NASDAQ:RNTX Rein Therapeutics Q4 2024 Earnings Results & Report $0.56 -0.05 (-7.59%) Closing price 04:00 PM EasternExtended Trading$0.56 0.00 (-0.18%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Rein Therapeutics reported Q4 2024 earnings on April 7, 2025. The company reported EPS of -$0.26. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ4 2024Report DateApril 7, 2025TimeAfter Market Closes Rein Therapeutics EPS ResultsActual EPS-$0.26Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AEPS Beat Rate3 of last 5 quartersRein Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesEarnings HistoryCompany Profile Rein Therapeutics Q4 2024 Earnings FAQ Did Rein Therapeutics beat earnings estimates for Q4 2024? Rein Therapeutics (NASDAQ:RNTX) reported earnings of -$0.26 per share for Q4 2024. The report was announced on Monday, April 7, 2025. Rein Therapeutics Earnings HeadlinesRein Therapeutics to Present at the Guggenheim 3rd Annual Healthcare Innovation ConferenceNovember 2, 2026 | globenewswire.comRein Therapeutics Inc. (NASDAQ:RNTX) Stock Has Consensus Target Price of $6.00 According to AnalystsNovember 2, 2026 | americanbankingnews.comSocial Security’s trust fund runs short in 2032. Guess who controls Congress.Social Security's retirement trust fund is projected to run dry in late 2032, per the 2026 Trustees Report. After that, only about 78% of scheduled benefits can be paid unless Congress acts. Higher taxes, smaller checks or more borrowing are all on the table. The morning after Democrats took Congress, gold jumped almost 3% and silver jumped 4%. If you count on Social Security for any part of your retirement, a backup plan matters before 2032.November 12 at 1:00 AM | Priority Gold (Ad)Rein Therapeutics to Present Late-Breaking Poster at the European Respiratory Society (ERS) 2026 CongressSeptember 4, 2026 | globenewswire.comRein Therapeutics to Present at Upcoming September Investor ConferencesSeptember 3, 2026 | globenewswire.comRein Therapeutics Receives U.S. FDA Fast Track Designation for LTI-03 in Idiopathic Pulmonary FibrosisAugust 20, 2026 | globenewswire.comSee More Rein Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Rein Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Rein Therapeutics and other key companies, straight to your email. Email Address About Rein TherapeuticsRein Therapeutics (NASDAQ:RNTX), Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for serious pulmonary and fibrotic diseases. The company’s research is centered on therapies intended to address the underlying biological mechanisms that drive tissue scarring and chronic disease progression. Its lead investigational product is bexotegrast, an oral small-molecule inhibitor of the integrins αvβ1 and αvβ6. Rein Therapeutics is evaluating bexotegrast in clinical development for conditions including idiopathic pulmonary fibrosis, a progressive lung disease, and primary sclerosing cholangitis, a chronic disease that affects the bile ducts and can lead to liver damage. Bexotegrast remains an investigational therapy and has not been approved for commercial use. The company’s development strategy is focused on advancing therapies for diseases with significant unmet medical needs, with clinical activities directed toward relevant patient populations and healthcare markets. Rein Therapeutics is headquartered in the United States. Publicly available information about the company’s broader product pipeline and leadership history is limited.View Rein Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Hims & Hers Bounced Back 9%, But Its Earnings Reveal a Costly Trade-OffSix Flags Lost $366 Million in Q3—Its Insiders Just Went Shopping3 Pharmaceutical Stocks That Offer Safety and GrowthKeeping AI Cool: AAON Rides the AI Heatwave to Record GrowthPalantir’s Real Washington Risk Isn’t the Budget—It’s OversightCoreWeave's Backlog Is Surging—Can the Stock Follow?Can Constellation Energy's Contracts Power a Stock Rebound? Upcoming Earnings Mizuho Financial Group (11/13/2026)Mitsubishi UFJ Financial Group (11/13/2026)Sumitomo Mitsui Financial Group (11/13/2026)Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026)Lowe's Companies (11/18/2026)PDD (11/18/2026)TJX Companies (11/18/2026)Target (11/18/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
